High serum concentration of estradiol may be a risk factor of prostate enlargement in aging male in China

References

• Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011;82:184–199.
   PubMed Web of Science ®Google Scholar
• Litman HJ, McKinlay JB. The future magnitude of urological symptoms in the USA: projections using the Boston Area Community Health survey. BJU Int. 2007;100:820–825.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20:S11–S18.
   PubMed Web of Science ®Google Scholar
• Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61:2–7.
   PubMed Web of Science ®Google Scholar
• Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology. 2008;72:247–254.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–2398.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008;180:1030–1032.
   PubMed Web of Science ®Google Scholar
• Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:461–475.
   PubMed Web of Science ®Google Scholar
• Wynder JL, Nicholson TM, DeFranco DB, et al. Estrogens and male lower urinary tract dysfunction. Curr Urol Rep. 2015;16:61.
   PubMed Web of Science ®Google Scholar
• Wu JH, Jiang XR, Liu GM, et al. Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats. Toxicol Ind Health. 2011;27:810–819.
   PubMed Web of Science ®Google Scholar
• Bélanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 1994;79:1086–1090.
   PubMed Web of Science ®Google Scholar
• Bernoulli J, Yatkin E, Konkol Y, et al. Prostatic inflammation and obstructive voiding in the adult Noble rat: impact of the testosterone to estradiol ratio in serum. Prostate. 2008;68:1296–1306.
   PubMed Web of Science ®Google Scholar
• Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest. 2011;34:232–243.
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–731.
   PubMed Web of Science ®Google Scholar
• Lenzi A, Balercia G, Bellastella A, et al. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest. 2009;32:934–938.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Rastre lli G, Corona G, et al. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014;37:313–322.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2011;14:53–58.
   PubMed Web of Science ®Google Scholar
• Corona G, Vignozzi L, Rastre lli G, et al. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014:329456.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–320.
   PubMed Web of Science ®Google Scholar
• Vignera SL, Condorelli RA, Russo GI, et al. Endocrine control of benign prostatic hyperplasia. Andrology. 2016;4:404–411.
   PubMed Web of Science ®Google Scholar
• Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73:233–244.
   PubMed Web of Science ®Google Scholar
• McPherson SJ, Ellem SJ, Risbridger GP. Estrogen-regulated development and differentiation of the prostate. Differentiation. 2008;76:660–670.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ito K, Suzuki T, et al. Synergistic effects of estrogen and androgen on the prostate: effects of estrogen on androgen- and estrogen-receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens. Prostate. 1995;26:151–163.
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Kanno J. Increase in prostate stem cell antigen expression in prostatic hyperplasia induced by testosterone and 17β-estradiol in C57BL mice. J Steroid Biochem Mol Biol. 2016;158:56–62.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009;12:160–165.
   PubMed Web of Science ®Google Scholar
• Nukui M, Takada H, Nakagawa S. Cross-sectional analysis between prostate volumes and serum sex hormones in Japanese men attending a urological clinic. Aging Male. 2016;19:148–154.
   PubMed Web of Science ®Google Scholar
• Roberts RO, Rhodes T, Klee GG, et al. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate. 2004;61:124–131.
   PubMed Web of Science ®Google Scholar
• Kim MK, Zhao C, Kim SD, et al. Relationship of sex hormones and nocturia in lower urinary tract symptoms induced by benign prostatic hyperplasia. Aging Male. 2012;15:90–95.
   PubMed Web of Science ®Google Scholar
• Nicholson TM, Moses MA, Uchtmann KS, et al. Estrogen receptor-alpha is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J Urol. 2015;193:722–729.
   PubMedGoogle Scholar
• Nicholson TM, Sehgal PD, Drew SA, et al. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Differentiation. 2013;85:140–149.
   PubMed Web of Science ®Google Scholar
• Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology. 2009;150:4594–4605.
   PubMed Web of Science ®Google Scholar